featured
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study
JAMA Oncol 2022 Jul 21;[EPub Ahead of Print], BA Derman, A Kansagra, J Zonder, AT Stefka, DL Grinblatt, LD Anderson, S Gurbuxani, S Narula, S Rayani, A Major, A Kin, K Jiang, T Karrison, J Jasielec, AJ JakubowiakFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.